Sevion Therapeutics, Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Technologies
      • Genomics-Proteomics
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals

Other Names/Subsidiaries

  • Fabrus, Inc.
  • Senesco Technologies, Inc.
See more in Biomedtracker

Latest on Sevion Therapeutics, Inc.

Scrip

Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs

 
• By Mandy Jackson

Five biopharmaceutical companies were expected to go public in the US during the week of 17-21 June, but only four launched initial public offerings and one firm – the one with the most advanced drug

Scrip

Early Stage Candidates Carving Out New Routes In Cystic Fibrosis

 
• By Jo Shorthouse

There is little doubt that Vertex Pharmaceuticals Inc. ’s cystic fibrosis transmembrane conductance regulator (CFTR) modulators Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor) have change

Scrip

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer

 
• By Mandy Jackson

The obesity market has not generated any blockbuster success stories for the biopharmaceutical industry, but Vivus Inc. still sells the prescription weight loss drug Qsymia (phentermine and topira

Scrip

Enteric Fever, Plague Vaccines From Synthetic Biology Firm Near Clinical Studies

 
• By John Davis

Phase I clinical studies of Prokarium 's two novel oral thermostable vaccines, against enteric fever (typhoid plus paratyphoid) and plague, are expected to start in 2019, says Ted Fjallman, CEO of th